fruquintinib
Selected indexed studies
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. (Lancet, 2023) [PMID:37331369]
- Fruquintinib. (, 2006) [PMID:38051798]
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. (JAMA, 2018) [PMID:29946728]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. (2023) pubmed
- Fruquintinib. (2006) pubmed
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. (2018) pubmed
- Fruquintinib. (2012) pubmed
- Fruquintinib for Adult Patients With Metastatic Colorectal Cancer. (2025) pubmed
- Fruquintinib: First Global Approval. (2018) pubmed
- Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. (2024) pubmed
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. (2025) pubmed
- Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. (2025) pubmed
- Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? (2024) pubmed